



FACT SHEET As of 12/31/24

# PROSHARES ULTRA NASDAQ BIOTECHNOLOGY

## Fund objective

ProShares Ultra Nasdaq Biotechnology seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology® Index.

## Fund details

Inception Date	4/7/10
Trading Symbol	BIB
Intraday Symbol	BIB.IV
Bloomberg Index Symbol	NBI
CUSIP	74347R214
Exchange	NASDAQ
Net Assets	\$60.74 million
Gross Expense Ratio	1.14%
Net Expense Ratio <sup>1</sup>	0.95%

## Uses for magnified exposure

Some uses for magnified exposure:

- Seeking magnified gains (will also magnify losses)
- Getting a target level of exposure for less cash
- Overweighting a market segment without additional cash


## Fund performance and index history<sup>2</sup>

This ProShares ETF seeks daily investment results that correspond, before fees and expenses, to 2x the daily performance of its underlying benchmark (the "Daily Target"). While the Fund has a daily investment objective, you may hold Fund shares for longer than one day if you believe it is consistent with your goals and risk tolerance. For any holding period other than a day, your return may be higher or lower than the Daily Target. These differences may be significant. Smaller index gains/losses and higher index volatility contribute to returns worse than the Daily Target. Larger index gains/losses and lower index volatility contribute to returns better than the Daily Target. The more extreme these factors are, the more they occur together, and the longer your holding period while these factors apply, the more your return will tend to deviate. Investors should consider periodically monitoring their geared fund investments in light of their goals and risk tolerance.

	4Q 2024	Year to Date	1-Year	5-Year	10-Year	Fund Inception
ProShares Ultra Nasdaq Biotechnology NAV Total Return	-20.03%	-10.00%	-10.00%	-3.57%	-1.97%	13.97%
ProShares Ultra Nasdaq Biotechnology Market Price Total Return	-19.94%	-9.84%	-9.84%	-3.57%	-1.96%	13.98%
Nasdaq Biotechnology Index	-9.43%	-0.57%	-0.57%	3.40%	3.72%	11.34%

Periods greater than one year are annualized.


## Daily performance of BIB vs. index during 4Q 2024



Correlation<sup>3</sup> = 0.99  
Beta<sup>4</sup> = 2.00

The scatter graph charts the daily NAV-to-NAV results of the fund against its underlying index return on a daily basis.

## Daily return during 4Q 2024



*The performance quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance quoted. Performance data current to the most recent month-end may be obtained by calling 866.776.5125 or visiting ProShares.com. Index performance does not reflect any management fees, transaction costs or expenses. Indexes are unmanaged and one cannot invest directly in any index.*

**Carefully consider the investment objectives, risks, charges and expenses of ProShares before investing. This and other information can be found in their summary and full prospectuses. Read them carefully before investing. Obtain them from your financial professional or visit ProShares.com. ProShares are not suitable for all investors.**

<h2>Index description</h2>	<h3>Top 10 index companies</h3> <table border="1"> <thead> <tr> <th></th> <th>Weights</th> </tr> </thead> <tbody> <tr> <td>Gilead Sciences Inc.</td> <td>8.65%</td> </tr> <tr> <td>Amgen Inc.</td> <td>7.99%</td> </tr> <tr> <td>Regeneron Pharmaceuticals Inc.</td> <td>7.71%</td> </tr> <tr> <td>AstraZeneca plc-Sponsored ADR</td> <td>7.46%</td> </tr> <tr> <td>Alnylam Pharmaceuticals Inc.</td> <td>3.82%</td> </tr> <tr> <td>Biogen Inc.</td> <td>3.04%</td> </tr> <tr> <td>Illumina Inc.</td> <td>2.23%</td> </tr> <tr> <td>argenx SE-ADR</td> <td>2.12%</td> </tr> <tr> <td>Moderna Inc.</td> <td>1.99%</td> </tr> <tr> <td>Sanofi SA-ADR</td> <td>1.60%</td> </tr> </tbody> </table>			Weights	Gilead Sciences Inc.	8.65%	Amgen Inc.	7.99%	Regeneron Pharmaceuticals Inc.	7.71%	AstraZeneca plc-Sponsored ADR	7.46%	Alnylam Pharmaceuticals Inc.	3.82%	Biogen Inc.	3.04%	Illumina Inc.	2.23%	argenx SE-ADR	2.12%	Moderna Inc.	1.99%	Sanofi SA-ADR	1.60%
	Weights																							
Gilead Sciences Inc.	8.65%																							
Amgen Inc.	7.99%																							
Regeneron Pharmaceuticals Inc.	7.71%																							
AstraZeneca plc-Sponsored ADR	7.46%																							
Alnylam Pharmaceuticals Inc.	3.82%																							
Biogen Inc.	3.04%																							
Illumina Inc.	2.23%																							
argenx SE-ADR	2.12%																							
Moderna Inc.	1.99%																							
Sanofi SA-ADR	1.60%																							
<p>The Nasdaq Biotechnology Index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies.</p>																								
<h2>Index characteristics</h2>																								
<table border="1"> <tbody> <tr> <td>Number of Companies</td> <td>265</td> </tr> <tr> <td>Average Market Cap</td> <td>\$5.58 billion</td> </tr> <tr> <td>Price/Book Ratio</td> <td>4.16</td> </tr> <tr> <td>Dividend Yield</td> <td>0.88%</td> </tr> <tr> <td>Volatility<sup>5</sup></td> <td>19.26%</td> </tr> </tbody> </table>	Number of Companies	265	Average Market Cap	\$5.58 billion	Price/Book Ratio	4.16	Dividend Yield	0.88%	Volatility <sup>5</sup>	19.26%	<h3>Index sectors</h3> <table border="1"> <thead> <tr> <th></th> <th>Weights<sup>6</sup></th> </tr> </thead> <tbody> <tr> <td>■ Biotechnology</td> <td>80.14%</td> </tr> <tr> <td>■ Pharmaceuticals</td> <td>14.57%</td> </tr> <tr> <td>■ Life Sciences Tools &amp; Services</td> <td>4.51%</td> </tr> <tr> <td>■ Health Care Providers &amp; Services</td> <td>0.45%</td> </tr> <tr> <td>■ Health Care Equipment &amp; Supplies</td> <td>0.32%</td> </tr> </tbody> </table>		Weights <sup>6</sup>	■ Biotechnology	80.14%	■ Pharmaceuticals	14.57%	■ Life Sciences Tools & Services	4.51%	■ Health Care Providers & Services	0.45%	■ Health Care Equipment & Supplies	0.32%	
Number of Companies	265																							
Average Market Cap	\$5.58 billion																							
Price/Book Ratio	4.16																							
Dividend Yield	0.88%																							
Volatility <sup>5</sup>	19.26%																							
	Weights <sup>6</sup>																							
■ Biotechnology	80.14%																							
■ Pharmaceuticals	14.57%																							
■ Life Sciences Tools & Services	4.51%																							
■ Health Care Providers & Services	0.45%																							
■ Health Care Equipment & Supplies	0.32%																							
<p>For more information, visit <a href="http://ProShares.com">ProShares.com</a> or ask your financial professional</p>																								

<sup>1</sup>Expenses with Contractual Waiver through September 30, 2025. Without the fee waiver performance would likely be lower. <sup>2</sup>Returns are based on the composite closing price and do not represent the returns you would receive if you traded shares at other times. The first trading date is typically several days after the fund inception date. Therefore, NAV is used to calculate market returns prior to the first trade date. <sup>3</sup>"Correlation" is a measure of the strength and direction of a linear relationship between two variables. <sup>4</sup>"Beta" is a measure of the slope, which is the steepness of the line drawn through the fund return vs. the benchmark return on a daily basis.

<sup>5</sup>"Volatility" refers to annualized standard deviation, a statistical measure that captures the variations from the mean of an index's returns and that is often used to quantify the risk of the index over a specific time period. The higher the volatility, the more an index's returns fluctuate over time. <sup>6</sup>Sum of weightings may not equal 100% due to rounding.

**Investing involves risk, including the possible loss of principal.** ProShares are generally non-diversified and entail certain risks, including risk associated with the use of derivatives (swap agreements, futures contracts and similar instruments), imperfect benchmark correlation, leverage and market price variance. These risks may pose risks different from, or greater than, those associated with a direct investment in the securities underlying the funds' benchmarks, can increase volatility, and may dramatically decrease performance. Narrowly focused investments typically exhibit higher volatility. Technology companies may be subject to severe competition and product obsolescence. Please see the summary and full prospectuses for a more complete description of risks. **There is no guarantee any ProShares ETF will achieve its investment objective.**

ProShares may invest in equity securities and/or financial instruments (including derivatives) that, in combination, should have similar daily price return characteristics to the fund's benchmark. Derivative contracts are priced to include the underlying index yield and will not generate dividend income. Because ProShares invest in derivatives and other financial instruments, their dividend distributions may not reflect those of their applicable indexes.

"Nasdaq Biotechnology" is a registered trademark of The Nasdaq OMX Group Inc. ("Nasdaq OMX") and has been licensed for use by ProShares. ProShares have not been passed on by Nasdaq OMX or its subsidiaries or affiliates as to their legality or suitability. ProShares are not sponsored, endorsed, sold, or promoted by Nasdaq OMX or its subsidiaries or affiliates, and they make no representation regarding the advisability of investing in these products. **Nasdaq OMX AND ITS SUBSIDIARIES AND AFFILIATES MAKE NO WARRANTIES AND BEAR NO LIABILITY WITH RESPECT TO PROSHARES.** ProShares are distributed by SEI Investments Distribution Co., which is not affiliated with the fund's advisor.

The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property of MSCI Inc. ("MSCI") and Standard & Poor's, a division of The McGraw-Hill Companies Inc. ("S&P"). Neither MSCI, S&P nor any third party involved in making or compiling GICS or any GICS classifications makes any express or implied warranties or representations with respect thereto (or the results to be obtained by the use thereof).